Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA430933
Max Phase: Preclinical
Molecular Formula: C34H53N5O6
Molecular Weight: 627.83
Molecule Type: Small molecule
Associated Items:
ID: ALA430933
Max Phase: Preclinical
Molecular Formula: C34H53N5O6
Molecular Weight: 627.83
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)C[C@H](O)[C@H](O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C
Standard InChI: InChI=1S/C34H53N5O6/c1-22(2)16-29(40)30(41)26(17-23-12-8-6-9-13-23)37-32(43)28(19-25-20-35-21-36-25)38-31(42)27(18-24-14-10-7-11-15-24)39-33(44)45-34(3,4)5/h7,10-11,14-15,20-23,26-30,40-41H,6,8-9,12-13,16-19H2,1-5H3,(H,35,36)(H,37,43)(H,38,42)(H,39,44)/t26-,27-,28-,29-,30+/m0/s1
Standard InChI Key: RRTBHYJKYDWRDY-VFFRCKCKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 627.83 | Molecular Weight (Monoisotopic): 627.3996 | AlogP: 3.80 | #Rotatable Bonds: 15 |
Polar Surface Area: 165.67 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 6 |
#RO5 Violations: 2 | HBA (Lipinski): 11 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.32 | CX Basic pKa: 6.53 | CX LogP: 3.91 | CX LogD: 3.86 |
Aromatic Rings: 2 | Heavy Atoms: 45 | QED Weighted: 0.17 | Np Likeness Score: 0.19 |
1. Rosenberg SH, Dellaria JF, Kempf DJ, Hutchins CW, Woods KW, Maki RG, de Lara E, Spina KP, Stein HH, Cohen J.. (1990) Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site., 33 (6): [PMID:2187994] [10.1021/jm00168a009] |
2. Luly JR, BaMaung N, Soderquist J, Fung AK, Stein H, Kleinert HD, Marcotte PA, Egan DA, Bopp B, Merits I.. (1988) Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency., 31 (12): [PMID:3143009] [10.1021/jm00120a005] |
3. Luly JR, BaMaung N, Soderquist J, Fung AK, Stein H, Kleinert HD, Marcotte PA, Egan DA, Bopp B, Merits I.. (1988) Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency., 31 (12): [PMID:3143009] [10.1021/jm00120a005] |
4. Williams PD, Perlow DS, Payne LS, Holloway MK, Siegl PK, Schorn TW, Lynch RJ, Doyle JJ, Strouse JF, Vlasuk GP.. (1991) Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics., 34 (3): [PMID:2002469] [10.1021/jm00107a004] |
Source(1):